

CYCLOSPORIN A TREATMENT OF PSORIASIS

	Patient #301				Patient #302		Patient #304		
PSI score	9	9	7	10	8	3	9	6	3
Weeks	0	1	4	8	0	4	0	1	4
SCCA2	448	514	260	302	211	3	569	104	3
PI3	501	594	329	313	309	3	661	118	3
SCCA1	83	146	89	72	43	3	44	80	3
S100A9	482	565	318	296	381	14	646	284	3
SPRR2A	438	377	293	277	174	4	592	99	6
GIP2	15	11	18	18	88	4	106	21	3
GJB2	40	78	45	42	37	3	34	41	3
HAL	40	69	30	45	36	3	48	77	4
IFI56	12	5	11	11	26	3	14	12	2
MX1	30	27	28	23	27	5	57	20	3
S100A12	25	25	8	13	10	2	35	6	2
TGM3	113	103	67	77	42	3	122	23	7
IFNRG7A	17	4	12	9	18	2	20	11	3
HBP17	37	24	27	26	45	6	48	16	7
S100A7	424	618	268	262	363	67	596	365	5
TGM1	85	60	43	49	44	3	56	12	4
ATPIAL1	18	24	16	21	15	3	59	10	3
LKYHYD	16	21	14	11	8	3	21	7	3
SQLE	37	32	24	26	17	3	56	30	6
KCNC3	21	15	11	14	24	3	36	4	2
SPRR1B	295	410	223	203	234	20	393	159	49
LGALS3BP	35	39	26	21	24	6	39	26	3
PPI3	18	14	11	12	5	2	22	7	3
CYBA	5	3	7	4	4	3	3	9	4
PRSS6	139	100	95	77	49	5	145	56	17
S100A2	350	308	226	229	300	69	477	96	26
PLSCR1	12	7	7	8	11	2	18	3	2
KRT17	395	338	227	189	249	14	356	45	2
ID1	96	120	94	46	58	29	82	63	26
CRABP2	161	125	133	109	150	20	221	55	15
FABP5	178	231	193	173	120	35	201	186	54
RB1	10	13	9	6	10	4	14	8	4
CSNK1A1	12	33	18	20	10	4	16	21	5
IL4R	29	22	19	16	13	3	35	5	4
STAT1	21	37	16	16	13	4	40	37	6
TOP1	23	30	13	13	7	3	30	20	4
NP	38	34	27	26	20	7	47	15	7
GNA15	39	28	26	23	17	4	36	21	3
PGD	14	10	6	8	4	2	9	4	2
RANBP1	30	21	21	21	18	4	46	12	6
K238_PERML1	5	9	10	4	7	3	9	6	3
UBE2F	12	4	8	6	7	3	18	4	3

FIGURE 1

BENE	34	37	20	18	10	<u>5</u>	34	<u>11</u>	<u>5</u>
IRAK1	42	36	42	26	25	<u>9</u>	50	<u>40</u>	<u>10</u>
TUBB2	111	111	103	93	37	<u>15</u>	98	112	<u>34</u>
ELP1	27	35	21	24	7	<u>3</u>	36	25	<u>5</u>
IFI27SEP	161	97	119	92	149	<u>38</u>	185	<u>57</u>	<u>30</u>
PCSK4	46	56	24	39	21	<u>4</u>	45	31	<u>7</u>
K111_NUK34	73	53	48	44	27	<u>7</u>	73	41	<u>12</u>
EIF5	21	17	11	11	5	<u>2</u>	21	<u>9</u>	<u>4</u>
TSSC3	28	<u>13</u>	<u>11</u>	17	20	<u>4</u>	29	<u>8</u>	<u>4</u>
LDLR	20	<u>20</u>	<u>8</u>	<u>10</u>	15	<u>4</u>	19	11	<u>5</u>
GOT2	33	26	<u>20</u>	<u>22</u>	18	<u>5</u>	30	16	<u>6</u>
GARS	43	49	45	42	26	<u>11</u>	39	62	<u>15</u>
PHB	17	14	14	14	10	<u>2</u>	13	<u>3</u>	<u>2</u>
EIF2B	46	40	40	35	22	<u>8</u>	35	22	<u>8</u>
RAB1	20	26	12	15	6	<u>3</u>	22	16	<u>4</u>
EFELL2	8	10	6	6	4	<u>3</u>	7	5	<u>3</u>
STAT3	33	28	19	23	14	<u>5</u>	36	<u>8</u>	<u>3</u>
PPP2CA	17	11	11	11	8	<u>3</u>	22	14	<u>6</u>
OIAS	28	26	26	21	14	<u>7</u>	15	16	<u>10</u>
UBECS	21	16	15	14	13	<u>7</u>	38	<u>7</u>	<u>5</u>
EIF2A	31	24	<u>14</u>	<u>15</u>	11	<u>5</u>	28	<u>11</u>	<u>8</u>
PSMB10	30	<u>13</u>	<u>18</u>	<u>13</u>	20	<u>6</u>	39	<u>10</u>	<u>3</u>
PRKMK3	19	12	11	<u>8</u>	5	<u>4</u>	18	8	<u>6</u>
GSTP1	314	229	220	199	191	<u>52</u>	480	<u>79</u>	<u>25</u>
S100A11	175	92	<u>82</u>	105	98	<u>20</u>	165	<u>55</u>	<u>28</u>
CSTB	169	239	<u>130</u>	151	105	<u>11</u>	285	<u>68</u>	<u>19</u>
ATOX1	55	39	38	37	24	<u>10</u>	55	31	<u>11</u>
CDC25	20	15	<u>9</u>	<u>8</u>	11	<u>4</u>	21	11	<u>4</u>
LAD1	82	56	46	46	35	<u>11</u>	86	<u>33</u>	<u>14</u>
P55CDC	20	13	13	12	15	<u>6</u>	32	<u>5</u>	<u>4</u>
PRPHIH	54	43	42	41	24	<u>7</u>	67	<u>24</u>	<u>7</u>
PGAM1	124	138	105	90	62	<u>22</u>	123	<u>91</u>	<u>31</u>
TB3_1	17	15	10	13	6	<u>4</u>	15	9	<u>3</u>
SCYA4	4	6	4	4	4	<u>3</u>	9	4	<u>3</u>
E_23773	13	12	8	8	8	<u>3</u>	13	9	<u>3</u>
MDF1	6	11	6	<u>3</u>	5	<u>3</u>	5	4	<u>2</u>
CASP	9	10	<u>3</u>	7	9	<u>3</u>	15	<u>7</u>	<u>4</u>
GPX3	38	30	29	20	25	<u>6</u>	43	<u>14</u>	<u>5</u>
EIF5A	3	4	3	4	8	<u>3</u>	4	<u>3</u>	<u>2</u>
CBR	15	<u>36</u>	<u>7</u>	17	16	<u>8</u>	21	<u>49</u>	<u>13</u>
COX5A	40	35	32	28	16	<u>4</u>	51	30	<u>6</u>
HSN	76	78	51	54	51	<u>24</u>	63	44	<u>17</u>
PSMHSC7	70	44	41	41	27	<u>11</u>	61	<u>20</u>	<u>14</u>
UQCRFS1	45	46	33	36	23	<u>8</u>	43	<u>47</u>	<u>15</u>
MSE55	20	<u>10</u>	15	13	13	<u>4</u>	15	<u>7</u>	<u>2</u>
CYB561	5	<u>5</u>	3	4	4	<u>2</u>	6	4	<u>3</u>
CDKN3	7	8	5	7	6	<u>3</u>	17	<u>3</u>	<u>3</u>
CD48	6	4	4	4	7	<u>3</u>	4	5	<u>3</u>
SEC23B	13	<u>6</u>	8	7	4	<u>2</u>	18	<u>3</u>	<u>3</u>
MAGEP15	18	<u>24</u>	14	14	8	<u>4</u>	15	<u>16</u>	<u>4</u>
DLD	9	11	<u>4</u>	7	5	<u>4</u>	6	10	<u>4</u>

FIGURE 1 CONT.

P4HB	120	115	88	73	46	31	149	76	25
TPH1	139	87	80	102	74	29	144	41	22
BTG3	21	27	22	19	14	6	19	20	10
ARF6	6	10	9	8	7	4	7	11	4
PYRIDK	10	2	4	4	4	2	13	2	2
ITBA2	16	10	14	8	8	3	23	10	4
CSNK1E	4	11	9	6	10	5	6	21	8
SDC4	24	15	16	15	16	18	22	13	17
TESK1	4	3	2	2	3	4	2	3	4
SPTAN1	9	4	6	4	4	4	4	5	6
METPEP	37	17	22	43	23	46	42	32	38
TMEM1	2	2	3	3	2	7	2	4	5
KRT2A	85	62	157	180	56	188	172	410	230
CRIP1	14	4	16	10	9	13	11	7	15
CST6	54	39	61	47	23	36	102	136	83
IGGFCBP	2	3	3	3	2	9	3	4	5



 = genes that increase in gene expression greater than 2 fold when compared to uninvolved skin
 = genes that decrease in gene expression greater than 2 fold when compared to uninvolved skin

FIGURE 1 CONT.

RhIL-11 TREATMENT OF PSORIASIS

	Patient #202					Patient #203					Patient #208			
PSI score	11	11	9	9	9	10	10	7	4	4	7	6	6	5
Weeks	0	1	4	8	12	0	1	4	8	12	0	1	4	8
SCCA2	413	421	302	451	175	281	265	258	89	3	179	235	43	71
PI3	407	633	523	567	299	477	249	280	82	3	199	290	84	124
SCCA1	98	127	152	61	59	68	112	123	46	12	84	101	57	56
SI00A9	624	580	474	623	501	404	348	466	392	12	455	345	261	306
SPRR2A	514	401	420	532	312	219	226	237	180	11	194	191	99	101
G1P2	147	116	129	100	34	26	14	21	6	2	7	10	3	3
GJB2	68	83	85	55	31	38	58	45	23	9	36	50	26	18
HAL	41	41	64	61	32	43	70	91	40	13	69	47	33	40
IFI56	45	31	26	40	18	18	11	10	4	3	4	4	3	4
MX1	88	92	91	70	38	33	29	22	12	4	21	20	7	11
SI00A12	17	9	18	9	4	20	19	12	5	2	9	10	4	4
TGM3	56	65	50	80	69	61	13	28	33	7	55	25	8	18
IFNRG7A	30	18	22	19	13	12	8	3	4	2	3	3	3	2
HBP17	25	48	36	35	28	90	27	38	36	10	17	18	9	7
SI00A7	613	609	489	666	531	465	455	519	518	86	513	384	352	359
TGM1	46	63	51	36	31	47	24	32	20	4	22	24	6	11
ATPIAL1	23	18	24	29	18	20	19	30	8	4	20	25	9	10
LKVHYD	11	11	14	13	6	14	21	13	6	3	9	10	4	6
SQLE	45	55	43	34	13	36	23	43	19	5	27	17	7	11
KCN3	17	7	9	10	5	14	7	8	4	2	4	5	3	3
SPRR1B	455	420	366	533	322	325	219	203	283	57	149	180	90	118
LGALS3BP	43	54	48	49	37	21	8	21	10	4	15	9	3	6
PP3	20	18	21	18	6	21	4	9	9	2	4	6	3	3
CYBA	17	11	19	30	12	8	9	18	7	2	6	9	3	6
PRSS6	84	100	106	68	50	87	62	87	49	17	81	40	23	39
SI00A2	275	289	271	176	163	426	361	273	167	55	177	194	166	108
P1.SCR1	14	12	24	6	6	6	10	9	2	2	5	5	3	3
KRT17	361	346	250	190	115	240	219	182	54	16	115	200	48	53
ID1	113	82	138	73	48	58	59	94	52	16	48	48	16	32
CRABP2	96	112	118	175	117	135	89	99	108	21	68	72	33	41
FABP5	151	185	207	206	147	202	155	199	191	97	172	134	129	121
RB1	14	13	14	15	10	11	8	9	8	3	6	6	4	4
CSNK1A1	22	27	38	26	22	21	14	30	16	3	18	15	4	9
IL4R	15	19	12	16	12	17	7	9	6	4	11	8	4	6
STAT1	41	30	44	37	16	23	49	42	18	9	31	23	18	22
TOP1	29	20	31	26	9	27	26	24	15	4	17	17	9	12
NP	33	35	35	36	22	49	26	35	34	9	24	18	7	11
GNA15	31	19	22	42	25	37	10	18	16	4	16	15	6	10
PGD	18	7	18	17	6	15	6	13	10	2	6	8	2	4
RANBP1	34	23	21	25	24	18	10	15	16	2	13	14	2	4
K238_PERML1	11	11	13	11	5	6	7	7	3	3	7	10	3	4
UBE2F	15	9	7	11	7	17	4	9	3	3	5	4	3	3
BENE	25	41	36	23	16	37	28	28	19	7	22	15	12	10
IRAK1	54	45	40	44	33	55	38	36	32	12	37	22	23	17
TUBB2	125	116	118	131	68	76	99	78	63	32	72	48	46	41
ELP1	23	24	25	38	18	31	29	30	28	7	20	18	6	9
IFI27SEP	188	189	182	300	163	118	76	78	133	23	60	66	27	45
PCSK4	25	37	36	26	11	25	46	34	13	9	26	26	13	14
K111_NUK34	41	46	47	50	25	48	32	47	31	5	33	25	6	12
EIF5	15	14	16	15	9	12	12	13	9	3	10	8	4	5
TSSC3	40	15	38	17	14	31	18	23	11	6	17	21	4	9
LDLR	17	16	23	21	10	31	20	22	19	6	13	16	6	7
GOT2	17	28	29	22	16	37	22	30	19	6	23	18	12	12
GARS	43	56	60	66	35	50	80	71	53	26	65	45	44	38
PHB	13	16	11	13	11	13	4	14	7	2	9	10	3	4
EIF2B	27	42	32	49	27	52	27	39	35	9	26	20	14	13
RAB1	20	22	23	27	13	21	12	17	21	3	13	10	4	5
EFELL2	10	6	10	12	8	11	8	6	11	3	9	6	3	5
STAT3	13	16	19	21	11	24	9	10	16	5	12	11	4	4
PPP2CA	17	10	12	10	6	10	13	13	9	4	10	7	6	7
OIAS	17	15	25	25	25	30	15	17	18	4	20	13	6	10
UBECS	21	12	21	25	14	26	15	17	20	5	11	11	4	7
EIF2A	16	13	14	17	14	28	13	14	15	5	14	10	6	8
PSMB10	19	21	23	26	17	9	12	11	11	3	10	13	4	8

FIGURE 2

Upregulated = genes that increase in gene expression greater than 2 fold when compared to uninvolved skin
Downregulated = genes that decrease in gene expression greater than 2 fold when compared to uninvolved skin

FIGURE 2 CONT.




FIGURE 3





FIGURE 3 CONT.

A



B





FIGURE 4

A



B





FIGURE 5

C



D





FIGURE 5 CONT.

106050*00125360



Title: Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Psoriasis Filed: Herewith
Inventor: William L. Trepicchio, et al. Atty. Docket No.: GFN-5405
Attorney: Amy E. Mandragouras, Esq., Reg. No. 36,207, LAHIVE & COCKFIELD, LLP, 28 State Street, Boston, MA 02109-1784
Sheet 11 of 12
Express Mail Label No.: EL 746 157 896 US




FIGURE 7